A DOUBLE-BLIND COMPARATIVE-STUDY OF REMOXIPRIDE AND THIORIDAZINE IN THE ACUTE PHASE OF SCHIZOPHRENIA

被引：17

作者：

MCCREADIE, RG

TODD, N

LIVINGSTON, M

ECCLESTON, D

WATT, JAG

HERRINGTON, RN

TAIT, D

CROCKET, G

MITCHELL, MJ

HUITFELDT, B

机构：

[1] ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND

[2] GARTNAVEL ROYAL HOSP,GLASGOW,SCOTLAND

[3] LEVERNDALE HOSP,GLASGOW,SCOTLAND

[4] MURRAY ROYAL HOSP,PERTH,SCOTLAND

[5] ASTRA RES CTR,SODERTALJE,SWEDEN

[6] ASTRA CLIN RES UNIT,EDINBURGH,SCOTLAND

来源：

ACTA PSYCHIATRICA SCANDINAVICA | 1990年 / 82卷

关键词：

acute schizophrenia; remoxipride; thioridazine;

D O I：

10.1111/j.1600-0447.1990.tb05305.x

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Abstract Sixty‐one patients with acute schizophrenia received either remoxipride (75–375 mg daily) or thioridazine (150–750 mg daily) for 6 weeks. There was no statistically significant between‐drug difference in improvement in mental state, as measured by the Brief Psychiatric Rating Scale, although the trend favoured thioridazine; global assessment of illness severity at the last rating also favoured thioridazine. Sedation, anticholinergic effects, autonomic dysfunction, and weight gain were significantly more common in patients receiving thioridazine. Both drugs produced few extrapyramidal effects, but both were associated with cardiovascular changes in two patients; neither drug produced significant abnormalities in laboratory tests. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：136 / 137

页数：2